RNAZ
TransCode Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.06
−4.41%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-30.9%
Return on equity
-28.3%
Return on assets
-25.0%
Return on invested capital
0.00x
Asset turnover
-$5.0B
Cash from operations
$0.50
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026